Results 51 to 60 of about 175,288 (244)

Angiotensin II type 1 receptor antagonists and their combinations in the treatment of hypertension

South African Family Practice, 2012
No abstract available.
J.A. Ker
doaj   +1 more source

The Angiotensin II Type 1 Receptor-Associated Protein Attenuates Angiotensin II-Mediated Inhibition of the Renal Outer Medullary Potassium Channel in Collecting Duct Cells

Frontiers in Physiology, 2021
Adjustments in renal K+ excretion constitute a central mechanism for K+ homeostasis. The renal outer medullary potassium (ROMK) channel accounts for the major K+ secretory route in collecting ducts during basal conditions.
Juliano Zequini Polidoro, Nancy Amaral Rebouças, Adriana Castello Costa Girardi   +2 more
doaj   +1 more source

Oral Delivery Systems for Food‐Derived Bioactive Peptides: Enhancing Stability, Bioavailability, and Health Benefits

Advanced Science, EarlyView.
Advanced delivery systems—including nanoparticles, nanoemulsions, liposomes, and hydrogels—protect food‐derived bioactive peptides from gastrointestinal degradation and bitterness. These systems enable pH‐responsive release, enhance intestinal absorption, and improve therapeutic efficacy against oxidative stress, metabolic disorders, cancer, and ...
Yu Xu, Fan Li, Runan Zhao, Tao Shu, Weihong Min, Bei‐Wei Zhu   +5 more
wiley   +1 more source

Angiotensin II Type 1 Receptor Blocker Prevents Abdominal Aortic Aneurysm Progression in Osteoprotegerin‐Deficient Mice via Upregulation of Angiotensin (1–7)

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Angiotensin II type 1 receptor blockers (ARBs) have been shown to limit the growth of abdominal aortic aneurysm (AAA), but their efficacy is controversial.
Kohei Karasaki, Hiroki Kokubo, Batmunkh Bumdelger, Nobuchika Kaji, Chiemi Sakai, Mari Ishida, Masao Yoshizumi   +6 more
doaj   +1 more source

Internalization of Constitutively Active N111G Mutant of AT1 Receptor Induced by Angiotensin II–Receptor Antagonists Candesartan, Losartan, and Telmisartan: Comparison With Valsartan

Journal of Pharmacological Sciences, 2010
Based on radioligand binding and signal transduction assays in our previous study, we have determined the binding pattern and functional efficacy of the constitutively active mutant N111G of angiotensin II type 1 (AT1) receptor.
Mohiuddin Ahmed Bhuiyan, Murad Hossain, Takashi Nakamura, Masanobu Ozaki, Takafumi Nagatomo   +4 more
doaj   +1 more source

Angiotensin II type-1 receptor-associated protein interacts with transferrin receptor-1 and promotes its internalization

Scientific Reports, 2022
Kidney fibrosis is a common pathway that leads to chronic kidney disease. Angiotensin II type-1 receptor (AT1R)-associated protein (ATRAP) was originally identified as an AT1R-binding protein.
Eriko Abe, Akio Yamashita, Keigo Hirota, Takahiro Yamaji, Kengo Azushima, Shingo Urate, Toru Suzuki, Shohei Tanaka, Shinya Taguchi, Shunichiro Tsukamoto, Tatsuki Uehara, Hiromichi Wakui, Kouichi Tamura, Hidehisa Takahashi   +13 more
doaj   +1 more source

Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis

American Journal of Physiology-Renal Physiology, 2010
Angiotensin type 1 (AT1) receptor blocker (ARB) ameliorates progression of chronic kidney disease. Whether this protection is due solely to blockade of AT1, or whether diversion of angiotensin II from the AT1to the available AT2receptor, thus potentially enhancing AT2receptor effects, is not known.
Takashi, Naito, Li-Jun, Ma, Haichun, Yang, Yiqin, Zuo, Yiwei, Tang, Jee Young, Han, Valentina, Kon, Agnes B, Fogo   +7 more
openaire   +3 more sources

Clinical Outcomes and Patient Experiences With Celiprolol Therapy in Vascular Ehlers–Danlos Syndrome: The First Non‐European Cohort

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Vascular Ehlers–Danlos syndrome (vEDS) is a hereditary connective tissue disorder caused by heterozygous pathogenic variants in COL3A1. European studies have shown that celiprolol may reduce the risk of life‐threatening vascular events, but outcomes in non‐European populations and the therapy's psychological impact remain unclear. We conducted
Megumi Furuhata‐Yoshimura, Tomomi Yamaguchi, Tomoki Kosho   +2 more
wiley   +1 more source

A Novel NR3C1 Frameshift Variant Associated With Familial Glucocorticoid Resistance Syndrome: An Integrated Analysis of Steroid Profiling and Structural Modeling

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Glucocorticoid resistance syndrome (GRS) is a rare hereditary disorder caused by pathogenic variants in NR3C1, characterized by marked phenotypic heterogeneity and frequent misdiagnosis as primary aldosteronism or subclinical Cushing's syndrome.
Sufang Yun, Zhifeng Zhu, Fengye Zhou, Ying Liu, Chunfang Liang, Haitao Ju, Lin Lu, Zhaoli Yan   +7 more
wiley   +1 more source

Adenoviral delivery of angiotensin-(1-7) or angiotensin-(1-9) inhibits cardiomyocyte hypertrophy via the mas or angiotensin type 2 receptor. [PDF]

PLoS ONE, 2012
The counter-regulatory axis of the renin angiotensin system peptide angiotensin-(1-7) [Ang-(1-7)] has been identified as a potential therapeutic target in cardiac remodelling, acting via the mas receptor.
Monica Flores-Muñoz, Bruno M D C Godinho, Abdulaziz Almalik, Stuart A Nicklin   +3 more
doaj   +1 more source